Goyal RK, Zhang J, Davis KL, Sluga-O'Callaghan M, Kaufman PA. Early real-world treatment patterns and clinical outcomes in patients with metastatic breast cancer treated with eribulin after prior immuno-oncology or antibody–drug conjugate therapy. Clin Breast Cancer. 2023 Nov 16;15:855-65. doi: 10.2147/BCTT.S422025
Simpson E, Eckert L, Gadkari A, Mallya UG, Yang M, Nelson L, Brown M, Reaney M, Mahajan P, Guillemin I, Boguniewicz M, Pariser D. Validation of the Atopic Dermatitis Control Tool (ADCT©) using a longitudinal survey of biologic-treated patients with atopic dermatitis. BMC Dermatology. 2019 Nov 6;19(1):15. doi: 10.1186/s12895-019-0095-3
Brufsky A, Mitra D, Davis KL, Nagar SP, McRoy L, Cotter MJ, Stearn V. Treatment patterns and outcomes associated with palbociclib plus letrozole for postmenopausal women with HR-/HER2– advanced breast cancer enrolled in an expanded access program. Clin Breast Cancer. 2019 Oct;19(5):317-25. doi: 10.1016/j.clbc.2019.04.005
Song W, Musetti SN, Huang L. Nanomaterials for cancer immunotherapy. Biomaterials. 2017 Dec;148:16-30. doi: 10.1016/j.biomaterials
Luo C, Miao L, Zhao Y, Musetti S, Wang Y, Shi K, Huang L. A novel cationic lipid with intrinsic antitumor activity to facilitate gene therapy of TRAIL DNA. Biomaterials. 2016 Sep;102:239-48. doi: 10.1016/j.biomaterials.2016.06.030
Castellsague J, García-Rodríguez LA, Duque A, Perez-Gutthann S. Risk of severe cutaneous disorders in users of oral antifungals. BMC Dermatology. 2002 Nov 28;2(14). doi: 10.1186/1471-5945-2-14
Castellsague J, Garcia-Rodriuez LA, Duque A, Perez S. Risk of serious skin disorders among users of oral antifungals: a population-based study. BMC Dermatology. 2002;2:14.